Denise M. Wolf

Also affiliated with University of San Francisco, University of California, Berkeley

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile

13.4Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

Cell(2018)10.1016/j.cell.2018.02.052

Top 2%

8.1DataRank

Top 2%3980 citations

Katherine A. Hoadley, Laila M. Poisson, Alexander J. Lazar, Andrew D. Cherniack, Albert J. Kovatich +866 more

Papers

Driven by 37 papers — median percentile 96. Top paper: “An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics”.

An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

Cell(2018)10.1016/j.cell.2018.02.052

Top 2%

8.1DataRank

Top 2%3980 citations

Katherine A. Hoadley, Laila M. Poisson, Alexander J. Lazar, Andrew D. Cherniack, Albert J. Kovatich +866 more

Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies

Cancer Cell(2022)10.1016/j.ccell.2022.05.005

Top 4%

4.9DataRank

Top 4%329 citations

Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Pei Rong Evelyn Lee +28 more

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types

Nature Communications(2019)10.1038/s41467-019-11415-2

N/A

4.4DataRank · unranked

165 citations

BIN CHEN, Dvir Aran, J. Charalel, L. J. van ‘t Veer, Atul Janardhan Butte +6 more

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

npj Breast Cancer(2022)10.1038/s41523-022-00493-z

N/A

0.900DataRank · unranked

27 citations

Andres Forero‐Torres, Douglas Yee, Christina Yau, Denise M. Wolf, John Park +44 more

Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial

Breast Cancer Research and Treatment(2023)10.1007/s10549-023-06914-2

N/A

0.441DataRank · unranked

7 citations

Rebecca Shatsky, Richard B. Schwab, Anne M. Wallace, Denise M. Wolf, Gillian L. Hirst +7 more

PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial

JAMIA Open(2021)10.1093/jamiaopen/ooab038

Top 51%

0.346DataRank

Top 51%2 citations

David L. Gibbs, Kawther Abdilleh, Adam L. Asare, Smita Asare, Sara J. Venters +8 more

Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk

npj Breast Cancer(2021)10.1038/s41523-021-00239-3

N/A

0DataRank · unranked

53 citations

Wen Li, Denise M. Wolf, Christina Yau, Gillian L. Hirst, Lamorna Brown Swigart +12 more

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00337-2

N/A

0DataRank · unranked

29 citations

Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar +50 more

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

Annals of Oncology(2022)10.1016/j.annonc.2022.04.072

N/A

0DataRank · unranked

21 citations

Anna Mrukwa, Christina Yau, Denise M. Wolf, Y.-Y. Chen, Ronald Balassanian +26 more

Analytic pipelines to assess the relationship between immune response and germline genetics in human tumors

STAR Protocols(2022)10.1016/j.xpro.2022.101809

N/A

0DataRank · unranked

3 citations

Mohamad Saad, Carolina Heimann, Donglei Hu, Khalid Kunji, Jessica Roelands +7 more

Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.504

N/A

0DataRank · unranked

15 citations

Hope S. Rugo, Lajos Pusztai, Rita A. Mukhtar, A. Jo Chien, Christina Yau +7 more

Improved pathologic complete response rates for triple-negative breast cancer in the I-SPY2 Trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.591

N/A

0DataRank · unranked

6 citations

Rebecca Shatsky, Christina Yau, Denise M. Wolf, Rita Nanda, L. J. van ‘t Veer +4 more

Development and testing of a polygenic risk score for breast cancer aggressiveness

medRxiv(2022)10.1101/2022.08.26.22278957

N/A

0DataRank · unranked

2 citations

Jacquelyn Roger, Christina Yau, Denise M. Wolf, Gillian L. Hirst, Lamorna Brown Swigart +18 more

Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.510

N/A

0DataRank · unranked

1 citations

Amy S. Clark, Christina Yau, Denise M. Wolf, L. J. van ‘t Veer, Emily Douglas +10 more

Distribution of breast cancer molecular subtypes within receptor classifications: Lessons from the I-SPY2 Trial and FLEX Registry.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.592

N/A

0DataRank · unranked

1 citations

Paige Warner, Robert Hiatt, Scarlett Lin Gomez, L. J. van ‘t Veer, Allison Stover Fiscalini +11 more

A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF V600E colorectal tumors

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.10.20.512885

N/A

0DataRank · unranked

0 citations

Chloé E. Atreya, Changjun Wang, Bo Pan, Courtney A. Dreyer, Diede Brunen +20 more

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy

Cancer Cell(2023)10.1016/j.ccell.2023.04.008

N/A

0DataRank · unranked

175 citations

Lamorna Brown Swigart, Ziad Ahmed, Rosalyn W. Sayaman, Derrick Renner, Ekaterina Kalashnikova +26 more

ENPP1 is an innate immune checkpoint of the anticancer cGAMP–STING pathway in breast cancer

Proceedings of the National Academy of Sciences(2023)10.1073/pnas.2313693120

N/A

0DataRank · unranked

70 citations

Volker Böhnert, Alby J. Joseph, Valentino Sudaryo, Gemini Skariah, Jason Swinderman +9 more

A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors

Nature Cancer(2023)10.1038/s43018-022-00508-5

N/A

0DataRank · unranked

45 citations

Chloé E. Atreya, Changjun Wang, Bo Pan, Courtney A. Dreyer, Diede Brunen +20 more

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2256

N/A

0DataRank · unranked

20 citations

Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien +44 more

Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial

Cell Reports Medicine(2023)10.1016/j.xcrm.2023.101312

N/A

0DataRank · unranked

18 citations

Julia Wulfkuhle, Denise M. Wolf, Lamorna Brown Swigart, Christina Yau, Nicholas O’Grady +22 more

Development and testing of a polygenic risk score for breast cancer aggressiveness

npj Precision Oncology(2023)10.1038/s41698-023-00382-z

N/A

0DataRank · unranked

11 citations

Jacquelyn Roger, Christina Yau, Denise M. Wolf, Gillian L. Hirst, Lamorna Brown Swigart +18 more

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes

Frontiers in Oncology(2023)10.3389/fonc.2023.1192208

N/A

0DataRank · unranked

5 citations

Amrita Basu, Christina Yau, Denise M. Wolf, Hani Goodarzi, Sourav Bandyopadhyay +10 more

355P Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial

Annals of Oncology(2023)10.1016/j.annonc.2023.09.534

N/A

0DataRank · unranked

2 citations

Elizabeth Price, Sara J. Venters, Wěi Li, Denise M. Wolf, Jessica Gibbs +14 more

Memory in Microbes: Quantifying History-Dependent Behavior in a Bacterium

PLoS ONE(2023)10.1371/journal.pone.0001700

N/A

0DataRank · unranked

149 citations

Denise M. Wolf

Use of PROMIS to capture patient reported outcomes over time for patients on I-SPY2.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.611

N/A

0DataRank · unranked

2 citations

Hongmei Yu, Denise M. Wolf, Nisha Acharya, Susie Brain, Carol A. Simmons +8 more

Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.514

N/A

0DataRank · unranked

1 citations

Denise M. Wolf, Christina Yau, Emanuel F. Petricoin, Paula R. Pohlmann, Lajos Pusztai +10 more

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.03.30.534178

N/A

0DataRank · unranked

0 citations

Amrita Basu, Christina Yau, Denise M. Wolf, Hani Goodarzi, Sourav Bandyopadhyay +11 more

Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2928

N/A

0DataRank · unranked

13 citations

Ziad Ahmed, Rosalyn W. Sayaman, Lamorna Brown Swigart, Gillian L. Hirst, Christina Yau +13 more

Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101799

N/A

0DataRank · unranked

9 citations

Denise M. Wolf, Christina Yau, Lamorna Brown Swigart, Julie Wulfkuhle, Isela Gallagher +21 more

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors

Nature Communications(2025)10.1038/s41467-025-65432-5

N/A

0DataRank · unranked

6 citations

Nayelis A. Manon, Denise M. Wolf, Samuel Rivero-Hinojosa, Ziad Ahmed, Rosalyn W. Sayaman +20 more

MRI-Based Model for Personalizing Neoadjuvant Treatment in Breast Cancer

Tomography(2025)10.3390/tomography11030026

N/A

0DataRank · unranked

4 citations

Natsuko Onishi, Jessica Gibbs, Lisa J. Wilmes, Nu N. Le, Pouya Metanat +12 more

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival

Annals of Oncology(2020)10.1016/j.annonc.2020.11.007

N/A

0DataRank · unranked

445 citations

Lamorna Brown Swigart, H.-T. Wu, Gillian L. Hirst, Christina Yau, Denise M. Wolf +19 more

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survival

medRxiv(2020)10.1101/2020.02.03.20019760

N/A

0DataRank · unranked

41 citations

Lamorna Brown Swigart, Hsin-Ta Wu, Gillian L. Hirst, Christina Yau, Denise M. Wolf +18 more

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Cancer Cell(2021)10.1016/j.ccell.2021.05.009

N/A

0DataRank · unranked

335 citations

Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace +40 more

Germline genetic contribution to the immune landscape of cancer

Immunity(2021)10.1016/j.immuni.2021.01.011

N/A

0DataRank · unranked

177 citations

Mohamad Saad, Vésteinn Thórsson, Donglei Hu, Wouter Hendrickx, Jessica Roelands +21 more

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Nature Communications(2021)10.1038/s41467-021-26019-y

N/A

0DataRank · unranked

73 citations

Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, L. J. van ‘t Veer, Douglas Yee +46 more

Denise M. Wolf

Indexed papers

Top data-sharing exemplar

Papers